| 產(chǎn)品名稱 | Elafibranor - GFT505 |
| 產(chǎn)品貨號(hào) | Axon 2727 CAS [824932-88-9] MF C22H24O4SMW 384.49 Purity: 98% Soluble in 0.1N NaOH(aq) and DMSO Description The dual PPARα/δ agonist Elafibrinor (GFT505) (EC50 values of 45 nM and 175 nM for PPARα and PPARδ, respectively) is a liver-targeted insulin-sensitizer that is a drug candidate for the treatment of type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NAS). In animals, its protective effects are mediated by both PPAR-α-dependent and -independent mechanisms. KEYWORDS: Elafibranor | supplier | PPAR α/δ agonist | GFT505 | GFT 505 | GFT-505 | CAS [824932-88-9] | CAS [923978-27-2] | Metabolism | PPAR | Agonist | Receptors | Insulin | Diabetes | NAFLD | NAS | Steatohepatitis | Peroxisome Proliferator-activated Receptor |
| 產(chǎn)品價(jià)格 | 現(xiàn)貨詢價(jià)，電話：010-67529703 |
| 產(chǎn)品規(guī)格 | |
| 產(chǎn)品品牌 | axonmedchem |
| 產(chǎn)品概述 | |
| 產(chǎn)品詳情 |
Elafibranor - GFT505Axon 2727 CAS [824932-88-9] MF C22H24O4S
DescriptionThe dual PPARα/δ agonist Elafibrinor (GFT505) (EC50 values of 45 nM and 175 nM for PPARα and PPARδ, respectively) is a liver-targeted insulin-sensitizer that is a drug candidate for the treatment of type 2 diabetes, nonalcoholic fatty liver disease (NAFLD) and nonalcoholic steatohepatitis (NAS). In animals, its protective effects are mediated by both PPAR-α-dependent and -independent mechanisms. KEYWORDS: Elafibranor | supplier | PPAR α/δ agonist | GFT505 | GFT 505 | GFT-505 | CAS [824932-88-9] | CAS [923978-27-2] | Metabolism | PPAR | Agonist | Receptors | Insulin | Diabetes | NAFLD | NAS | Steatohepatitis | Peroxisome Proliferator-activated Receptor
Dual PPARα/δ agonist
Chemical name(E)-2-(2,6-Dimethyl-4-(3-(4-(methylthio)phenyl)-3-oxoprop-1-enyl)phenoxy)-2-methylpropanoic acid Parent CAS No.[824932-88-9] |
| 產(chǎn)品資料 |
